What is ifinatamab biosimilar research grade? Ifinatamab is a humanized IgG1-kappa monoclonal antibody against the human B7-H3 (CD276) protein, a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal (healthy) tissues. It was reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers. Ifinatamab biosimilar uses the same protein sequences as the therapeutic antibody ifinatamab.
